Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 18 de 18
Filter
1.
J Hosp Med ; 16(10): 623-627, 2021 10.
Article in English | MEDLINE | ID: mdl-34328846
2.
Acad Med ; 96(8): 1137-1145, 2021 08 01.
Article in English | MEDLINE | ID: mdl-33298691

ABSTRACT

The COVID-19 pandemic has had a profound impact on the nation's health care system, including on graduate medical education (GME) training programs. Traditionally, residency and fellowship training program applications involve in-person interviews conducted on-site, with only a minority of programs offering interviews remotely via a virtual platform. However, in light of the COVID-19 pandemic, it is anticipated that most interviews will be conducted virtually for the 2021 application cycle and possibly beyond. Therefore, GME training programs need to prepare for the transition to virtual interviews using evidence-based practices. At the University of California, San Francisco, a multidisciplinary task force was convened to review existing literature about virtual interviews and determine best practices. This article summarizes these findings, first discussing the advantages and disadvantages of the virtual interview format and then providing evidence-based best practices for GME training programs. Specifically, the authors make the following recommendations: develop a detailed plan for the interview process, consider using standardized interview questions, recognize and respond to potential biases that may be amplified with the virtual interview format, prepare your own trainees for virtual interviews, develop electronic materials and virtual social events to approximate the interview day, and collect data about virtual interviews at your own institution. With adequate preparation, the virtual interview experience can be high yield, positive, and equitable for both applicants and GME training programs.


Subject(s)
COVID-19 , Internship and Residency , COVID-19/epidemiology , Education, Medical, Graduate , Fellowships and Scholarships , Humans , Pandemics
3.
Psychoneuroendocrinology ; 88: 136-143, 2018 02.
Article in English | MEDLINE | ID: mdl-29268182

ABSTRACT

Disturbed sleep is a core feature of posttraumatic stress disorder (PTSD), characterized in part by decreased delta power sleep that may result from stress-related alterations in corticotropin releasing factor (CRF), hypothalamic pituitary adrenal axis (HPA) regulation and glucocorticoid signaling. Overnight HPA axis response mediating sleep disturbances in men and women with PTSD was examined using a metyrapone challenge. Metyrapone blocks cortisol synthesis, removing negative feedback, and increases the release of hypothalamic CRF and pituitary adrenocorticotropic hormone (ACTH). Laboratory-based polysomnography was used to monitor the sleep of 66 medically healthy, medication-free men and pre-menopausal follicular phase women including 33 with chronic PTSD (16 women and 17 men) and 33 age- and sex-matched controls (14 women and 19 men) over 3 consecutive nights. Participants completed an overnight metyrapone challenge after an adaptation and baseline night of sleep and ACTH was obtained by repeated blood sampling. Metyrapone resulted in a greater increase in ACTH and greater decreases in cortisol and delta spectral power sleep in PTSD subjects compared to controls, and a greater increase in ACTH in women compared to men. There was no sex difference in metyrapone effects on delta power sleep, and no significant metyrapone by PTSD by sex interactions with either ACTH or delta power sleep. Regression analyses indicated that a greater increase in ACTH response was associated with a greater decrease in delta power sleep response in PTSD subjects, but no such relationship was found in controls. The PTSD group difference was similar in men and women. These results suggest that stress-related alterations of the HPA axis in PTSD may contribute to sleep difficulties. Therapeutics that target the HPA axis may offer promise as a potential future treatment for PTSD and related sleep difficulties.


Subject(s)
Adrenocorticotropic Hormone/drug effects , Metyrapone/pharmacology , Sleep/physiology , Adrenocorticotropic Hormone/blood , Adult , Corticotropin-Releasing Hormone/metabolism , Cross-Sectional Studies , Female , Humans , Hydrocortisone/blood , Hypothalamo-Hypophyseal System/drug effects , Hypothalamo-Hypophyseal System/metabolism , Male , Pituitary-Adrenal System/drug effects , Pituitary-Adrenal System/metabolism , Polysomnography/methods , Sleep Wake Disorders , Stress Disorders, Post-Traumatic/blood , Stress Disorders, Post-Traumatic/drug therapy
4.
Sleep ; 40(1)2017 Jan 01.
Article in English | MEDLINE | ID: mdl-28364476

ABSTRACT

Objectives: To determine the interaction of age and habitual sleep duration in predicting cognitive performance in a large sample of participants aged 15 to 89 years. Methods: This study is a cross-sectional analysis of performance data gathered between January 2012 and September 2013. First-time players (N = 512823) of three internet cognitive training games measuring processing speed, working memory, visuospatial memory, and arithmetic participated in the study. Results: Performance was based on a measure of speed and accuracy for each game. The relationship between performance and self-reported habitual sleep duration was examined in the sample as a whole and across 10-year age groups starting at age 15 and ending at 75 and older. Performance peaked at 7 h of sleep duration for all three games in the sample as a whole, and the decrements in performance for sleep durations greater than 7 h were either comparable or greater in the youngest as compared to the oldest age groups. Conclusions: These findings challenge the hypothesis that deteriorating cognitive performance with long sleep duration is driven by medical comorbidities associated with aging. Further, these data are consistent with an optimal dose model of sleep and suggest that the model for the homeostatic recovery of cognitive function as a function of sleep duration should incorporate a curvilinear decline with longer duration sleep, indicating that there may be a cost to increased sleep. Replication and further research is essential for clarifying the sleep duration-cognition relationship in youth and adults of all ages.


Subject(s)
Aging , Cognition/physiology , Sleep/physiology , Adolescent , Adult , Age Factors , Aged , Aged, 80 and over , Aging/physiology , Aging/psychology , Cross-Sectional Studies , Female , Humans , Male , Middle Aged , Self Report , Task Performance and Analysis , Time Factors , Young Adult
5.
Psychosom Med ; 77(4): 383-91, 2015 May.
Article in English | MEDLINE | ID: mdl-25886830

ABSTRACT

OBJECTIVE: Posttraumatic stress disorder (PTSD) is associated with indicators of poor physical health and sleep disturbance. This study investigated the relationship between PTSD and metabolic risk factors and examined the role of sleep duration in medically healthy and medication-free adults. METHODS: Participants with PTSD (n = 44, mean age = 30.6 years) and control participants free of lifetime psychiatric history (n = 50, mean age = 30.3 years) recorded sleep using sleep diary for 10 nights and actigraphy for 7 nights. We assessed metabolic risk factors including fasting triglycerides, total cholesterol, low-density lipoprotein (LDL) cholesterol, and high-density lipoprotein cholesterol, as well as abdominal fat using dual-energy x-ray absorptiometry. RESULTS: PTSD was associated with shorter sleep duration (based on self-report, not actigraphy) and higher metabolic risks (controlling for body fat percentage), including increased triglycerides (p = .03), total cholesterol (p < .001), LDL cholesterol (p = .006), very low density lipoprotein cholesterol (p = .002), and cholesterol/high-density lipoprotein ratio (p = .024). In addition, sleep duration was associated with metabolic risks in PTSD (significant correlations ranged from r = -0.20 to r = -0.40) but did not fully account for the association between PTSD and metabolic measures. CONCLUSIONS: Metabolic risk factors are associated with PTSD even in early adulthood, which highlights the need for early intervention. Future longitudinal research should assess whether sleep disturbance in PTSD is a mechanism that contributes to heightened metabolic risk to elucidate the pathway from PTSD to higher rates of medical disorders such as obesity, diabetes, and heart disease.


Subject(s)
Metabolic Diseases/epidemiology , Sleep Wake Disorders/epidemiology , Stress Disorders, Post-Traumatic/epidemiology , Adult , Comorbidity , Female , Humans , Male , Metabolic Diseases/blood , Middle Aged , Risk Factors , Young Adult
6.
J Clin Endocrinol Metab ; 100(6): 2434-42, 2015 Jun.
Article in English | MEDLINE | ID: mdl-25825943

ABSTRACT

CONTEXT: Consumption of high-fructose diets promotes hepatic fatty acid synthesis (de novo lipogenesis [DNL]) and an atherogenic lipid profile. It is unclear whether these effects occur independent of positive energy balance and weight gain. OBJECTIVES: We compared the effects of a high-fructose, (25% of energy content) weight-maintaining diet to those of an isocaloric diet with the same macronutrient distribution but in which complex carbohydrate (CCHO) was substituted for fructose. DESIGN, SETTING, AND PARTICIPANTS: Eight healthy men were studied as inpatients for consecutive 9-day periods. Stable isotope tracers were used to measure fractional hepatic DNL and endogenous glucose production (EGP) and its suppression during a euglycemic-hyperinsulinemic clamp. Liver fat was measured by magnetic resonance spectroscopy. RESULTS: Weight remained stable. Regardless of the order in which the diets were fed, the high-fructose diet was associated with both higher DNL (average, 18.6 ± 1.4% vs 11.0 ± 1.4% for CCHO; P = .001) and higher liver fat (median, +137% of CCHO; P = .016) in all participants. Fasting EGP and insulin-mediated glucose disposal did not differ significantly, but EGP during hyperinsulinemia was greater (0.60 ± 0.07 vs 0.46 ± 0.06 mg/kg/min; P = .013) with the high-fructose diet, suggesting blunted suppression of EGP. CONCLUSION: Short-term high-fructose intake was associated with increased DNL and liver fat in healthy men fed weight-maintaining diets.


Subject(s)
Adipose Tissue/drug effects , Body Weight/drug effects , Dietary Carbohydrates/pharmacology , Fructose/pharmacology , Lipogenesis/drug effects , Liver/drug effects , Adipose Tissue/metabolism , Adiposity/drug effects , Adolescent , Adult , Aged , Glucose/metabolism , Humans , Lipid Metabolism/drug effects , Liver/metabolism , Male , Middle Aged , Young Adult
7.
J Clin Endocrinol Metab ; 100(4): 1664-71, 2015 Apr.
Article in English | MEDLINE | ID: mdl-25658017

ABSTRACT

CONTEXT: Short sleep duration is associated with an increased risk of type 2 diabetes. Subchronic sleep restriction (SR) causes insulin resistance, but the mechanisms and roles of specific tissues are unclear. OBJECTIVE: The purpose of this article was to determine whether subchronic SR altered (1) hepatic insulin sensitivity, (2) peripheral insulin sensitivity, and (3) substrate utilization. DESIGN: This was a randomized crossover study in which 14 subjects underwent 2 admissions separated by a washout period. Each admission had 2 acclimatization nights followed by 5 nights of either SR (4 hours time in bed) or normal sleep (8 hours time in bed). MAIN OUTCOME MEASURE/METHODS: Insulin sensitivity (measured by hyperinsulinemic-euglycemic clamp) and hepatic insulin sensitivity (measured by stable isotope techniques) were measured. In addition, we assayed stress hormone (24-hour urine free cortisol, metanephrine, and normetanephrine), nonesterified fatty acid (NEFA), and ß-hydroxybutyrate (ß-OH butyrate) levels. Resting energy expenditure (REE) and respiratory quotient (RQ) were measured by indirect calorimetry. RESULTS: Compared to normal sleep, whole-body insulin sensitivity decreased by 25% (P = .008) with SR and peripheral insulin sensitivity decreased by 29% (P = .003). Whereas hepatic insulin sensitivity (endogenous glucose production) did not change significantly, percent gluconeogenesis increased (P = .03). Stress hormones increased modestly (cortisol by 21%, P = .04; metanephrine by 8%, P = .014; normetanephrine by 18%, P = .002). Fasting NEFA and ß-OH butyrate levels increased substantially (62% and 55%, respectively). REE did not change (P = 0.98), but RQ decreased (0.81 ± .02 vs 0.75 ± 0.02, P = .045). CONCLUSION: Subchronic SR causes unique metabolic disturbances characterized by peripheral, but not hepatic, insulin resistance; this was associated with a robust increase in fasting NEFA levels (indicative of increased lipolysis), decreased RQ, and increased ß-OH butyrate levels (indicative of whole-body and hepatic fat oxidation, respectively). We postulate that elevated NEFA levels are partially responsible for the decrease in peripheral sensitivity and modulation of hepatic metabolism (ie, increase in gluconeogenesis without increase in endogenous glucose production). Elevated cortisol and metanephrine levels may contribute to insulin resistance by increasing lipolysis and NEFA levels.


Subject(s)
Insulin Resistance , Sleep Deprivation/metabolism , Adult , Chronic Disease , Cross-Over Studies , Female , Glucose/metabolism , Glucose Clamp Technique , Glucose Tolerance Test , Humans , Liver/metabolism , Male , Organ Specificity , Sleep/physiology , Young Adult
8.
Surgery ; 156(4): 806-12, 2014 Oct.
Article in English | MEDLINE | ID: mdl-25239323

ABSTRACT

BACKGROUND: The mechanisms by which bariatric surgery achieves weight loss (WL) are under scrutiny. We assessed changes in resting energy expenditure (REE) after gastric bypass (RYGB) and gastric banding (AGB) to determine if changes in REE are associated with WL and type of surgery. METHODS: Three groups of morbidly obese patients were studied: RYGB (n = 12), AGB (n = 8), and a control group that underwent caloric restriction alone (Diet, n = 10). Studies were performed at baseline and after 14 days in all groups and 6 months after RYGB and AGB. REE (kcal/day) was measured by indirect calorimetry and adjusted for body weight (Wt-REE), and lean body mass by dual-energy X-ray absorptiometry (LBM-REE). RESULTS: At baseline, REE did not differ significantly among groups (RYGB = 2,114 ± 337, AGB = 1,837 ± 154, Diet = 2,091 ± 363 kcal/day, P = .13). After 14 days, the groups had similar percent excess WL (%EWL). Neither Wt-REE nor LBM-REE changed significantly in any group. After 6 months %EWL was 49 ± 10% after RYGB and 21 ± 11% after AGB (P < .01); RYGB patients had greater increase in the percent of weight that was LBM (RYGB = 7.9 ± 3.0 vs. AGB = 1.6 ± 1.5%, P < .01). Wt-REE increased significantly only after RYGB (+2.58 ± 1.51 kcal/kg/day, P < .01). There was a significant correlation between changes in Wt-REE and %EWL (r = 0.670, P = .003). CONCLUSION: The increase in Wt-REE may be a factor supporting WL after RYGB.


Subject(s)
Basal Metabolism , Gastric Bypass , Gastroplasty , Obesity, Morbid/surgery , Weight Loss/physiology , Adult , Calorimetry, Indirect , Diet, Reducing , Female , Follow-Up Studies , Humans , Male , Middle Aged , Obesity, Morbid/diet therapy , Obesity, Morbid/physiopathology , Treatment Outcome
9.
Psychoneuroendocrinology ; 49: 171-81, 2014 Nov.
Article in English | MEDLINE | ID: mdl-25108160

ABSTRACT

BACKGROUND: Posttraumatic stress disorder (PTSD) is associated with a 2-4 fold increased risk of developing Type 2 diabetes mellitus. However, detailed assessments of glucose metabolism and insulin secretion in a study designed to minimize confounders are lacking. Furthermore, few studies examine potential mechanisms involved. We analyzed data from a case-control study of medically healthy, medication-free adults to determine whether individuals with PTSD had abnormal glucose or insulin response to oral glucose tolerance test (OGTT) compared to controls. Secondarily, we assessed potential mediators such as sleep, cortisol and adiponectin. METHODS: Data was analyzed from 92 age and gender-matched subjects (44 PTSD, 48 controls). Chronic PTSD was diagnosed using the Structured Clinical Interview for DSM-IV and Clinician Administered PTSD Scale. Subjects underwent 75-g OGTT, actigraphy and sleep diary (to quantify sleep duration), polysomnography (to assess slow wave sleep [SWS] and delta power), and overnight blood sampling (for cortisol and adiponectin). RESULTS: At baseline, individuals with PTSD had mildly increased insulin levels (by 19%, compared to controls, p=0.048) that was mediated primarily by weight. In response to OGTT, the PTSD group had higher levels of insulin at 120 min (by 44%, p=0.03) and insulin AUC (by 43%, p=0.015) compared to controls, after adjusting for confounders. Glucose levels were similar in the two groups. Although self-reported sleep duration, SWS, and delta power differed between PTSD subjects and controls, they did not mediate the effects of PTSD status on insulin response. CONCLUSION: In this case-control study, individuals with PTSD had a hyperinsulinemic response to oral glucose challenge compared to controls, suggestive of insulin resistance.


Subject(s)
Adiponectin/blood , Glucose Tolerance Test , Hydrocortisone/blood , Hyperinsulinism/blood , Stress Disorders, Post-Traumatic/metabolism , Actigraphy , Adult , Blood Glucose/metabolism , Case-Control Studies , Female , Humans , Male , Middle Aged , Polysomnography , Sleep/drug effects , Sleep/physiology , Stress Disorders, Post-Traumatic/blood , Stress Disorders, Post-Traumatic/physiopathology , Young Adult
10.
Psychopharmacology (Berl) ; 231(17): 3581-95, 2014 Sep.
Article in English | MEDLINE | ID: mdl-24952092

ABSTRACT

RATIONALE: Mechanisms contributing to sex differences in the regulation of acute stress responsivity and their effect on the increased incidence of posttraumatic stress disorder (PTSD) in women are poorly understood. The reproductive hormone, progesterone, through conversion to allopregnanolone (ALLO), suppresses the hypothalamic pituitary adrenal (HPA) axis and has potent anxiolytic effects. The potential that progesterone and allopregnanolone reactivity modulate HPA axis responses and account for sex differences in PTSD has not been previously examined. OBJECTIVE: The present study examined the effects of sex and PTSD on adrenocorticotropic hormone (ACTH), progesterone, and allopregnanolone responses to metyrapone and whether progesterone and allopregnanolone reactivity could affect the ACTH response in PTSD. METHODS: Healthy medication-free male and premenopausal follicular phase female participants with chronic PTSD (n = 43; 49 % female) and controls (n = 42; 50 % female) completed an overnight metyrapone challenge and ACTH, progesterone, and allopregnanolone were obtained by repeated blood sampling. RESULTS: The increase in ACTH response to metyrapone was higher in PTSD subjects compared to controls and in women compared to men. Contrary to our initial prediction of an inverse relationship, progesterone and allopregnanolone were positively associated with ACTH. Progesterone and allopregnanolone partially mediated the relationship between PTSD and ACTH. CONCLUSIONS: Our findings of increased ACTH to metyrapone in PTSD and in women may reflect heightened hypothalamic CRF hypersecretion. Progesterone and allopregnanolone partially mediated the ACTH response in PTSD. Further characterizing sex differences in these processes will advance our understanding of the pathophysiology of PTSD, and may ultimately lead to better-targeted, more effective treatment.


Subject(s)
Enzyme Inhibitors/therapeutic use , Metyrapone/therapeutic use , Neurotransmitter Agents/metabolism , Stress Disorders, Post-Traumatic/drug therapy , Stress Disorders, Post-Traumatic/metabolism , Adrenocorticotropic Hormone/blood , Adult , Feedback, Physiological/drug effects , Female , Humans , Hydrocortisone/blood , Hypothalamo-Hypophyseal System/drug effects , Male , Pituitary-Adrenal System/drug effects , Pregnanolone/blood , Progesterone/blood , Sex Characteristics , Young Adult
11.
PLoS One ; 8(9): e75205, 2013.
Article in English | MEDLINE | ID: mdl-24228086

ABSTRACT

CONTEXT: Short sleep duration is associated with adverse health outcomes, but the mechanisms involved are unknown. It has been postulated that short sleep duration may elevate cortisol levels, but studies have had conflicting results. It is unclear whether these differing findings may be due to methodological issues, such as assessment of sleep duration. Specifically, objective versus subjective methods of measuring habitual sleep duration may account for the conflicting results found in epidemiological studies. OBJECTIVE: Our goal was to determine whether habitual sleep duration, measured objectively (by actigraphy) and subjectively (by self-report), was associated with 24-hour urine free cortisol (UFC), a measure of integrated cortisol secretion. Our secondary goal was to determine whether slow wave sleep (SWS, determined by polysomnography) was associated with 24-hour UFC. DESIGN/SETTING: Cross sectional study of community dwelling older men. PATIENTS/PARTICIPANTS: 325 men (mean age = 76.6 years, SD = 5.5) from the Portland site of the MrOS Sleep Study, who underwent 24-hour urine collection, polysomnography, actigraphy and sleep questionnaire. PRIMARY OUTCOME: 24-hour UFC. RESULTS: In this study of community dwelling older men, self-reported sleep duration was inversely related to 24-hour UFC levels. Participants reporting <5 hours of habitual sleep had an adjusted mean 24-hour UFC of 29.8 ug, compared to 28.0 ug in participants reporting >5 to <8 hours of sleep 25.5 ug in those reporting >8 hours of habitual sleep. However, sleep duration determined by actigraphy was not associated with 24-hour UFC in either univariable or multivariable regression models. SWS was not associated with 24-hour UFC. CONCLUSION: Objectively measured (i.e., actigraphic) sleep duration is not associated with 24-hour UFC in these community dwelling older men. This finding, together with prior studies, suggests that elevated levels of integrated cortisol secretion is not the mechanisms by which short sleep duration leads to adverse health outcomes.


Subject(s)
Fractures, Bone , Hydrocortisone/urine , Sleep , Actigraphy , Aged , Aged, 80 and over , Cross-Sectional Studies , Humans , Male , Risk Factors , Self Report
12.
AIDS Res Treat ; 2012: 103072, 2012.
Article in English | MEDLINE | ID: mdl-22966425

ABSTRACT

HIV-infected individuals are at risk for decreased bone mineral density (BMD). The known risk factors for bone loss do not fully explain the increased risk in this population. There is emerging evidence that leptin, a hormone secreted by adipocytes, plays an important role in bone metabolism. Several studies have assessed the relationship between leptin and bone density in healthy adults, but there are few such studies in HIV-infected individuals. Furthermore, HIV infected individuals on antiretroviral therapy are at increased risk for altered fat distribution, which may impact the relationship between leptin and BMD. In a cross-sectional analysis of data in 107 HIV-infected men, we determined whether serum leptin levels were associated with whole-body BMD and bone mineral content measured by dual-energy X-ray absorptiometry (DEXA), after adjusting for confounders including body fat distribution. We found an inverse association between leptin and bone density in those with peripheral lipoatrophy, defined objectively as <3 kg appendicular fat by DEXA, but no such relationship was seen in those with >3 kg appendicular fat. This result suggests that fat distribution may modify the relationship between leptin and bone density.

13.
Prev Chronic Dis ; 9: E76, 2012.
Article in English | MEDLINE | ID: mdl-22440550

ABSTRACT

INTRODUCTION: Sleep problems, including insomnia, apnea, and restless legs syndrome, are common, burdensome, and under-recognized in the United States. We sought to examine the association of sleep problems with diabetes among community-dwelling US adults. METHODS: We examined self-reported sleep problems in 9,848 adults (aged ≥20 y) participating in the National Health and Nutrition Examination Survey 2005 through 2008. Sleep problem information was elicited via validated questionnaire. Diabetes was defined by self-reported diagnosis or glycohemoglobin of 6.5% or higher. Multivariable logistic regression with US population-based weighting was used to obtain adjusted odds ratios (ORs) and 95% confidence intervals (CIs) for various sleep problems by diabetes status. RESULTS: Sleep problems were common (>90% for any problem; 10%-40% for individual problems) overall, and people with diabetes were more likely than those without diabetes to report multiple problems (mean, 3.1 vs 2.5, respectively, P < .001). After adjustment for potential confounders (including demographics, body mass index, cardiovascular and kidney disease, and alcohol use), restless legs symptoms (OR, 1.40; 95% CI, 1.12-1.78), sleep apnea (OR, 1.45; 95% CI, 1.06-1.98), and nocturia (OR, 1.51; 95% CI, 1.22-1.87) were all positively associated with diabetes status. CONCLUSION: Diabetes is associated with a higher risk of sleep problems, including not only sleep apnea but also inadequate sleep, excessive sleepiness, leg symptoms, and nocturia, independent of body mass index. Clinicians should be aware of the high prevalence of sleep problems among their patients with diabetes and should consider screening and treatment, which may improve patients' quality of life.


Subject(s)
Diabetes Mellitus/epidemiology , Sleep Wake Disorders/epidemiology , Female , Humans , Logistic Models , Male , Middle Aged , Nutrition Surveys , Prevalence , Self Report , United States
14.
J Clin Endocrinol Metab ; 95(9): 4361-6, 2010 Sep.
Article in English | MEDLINE | ID: mdl-20610601

ABSTRACT

CONTEXT: HIV-infected patients on antiretroviral therapy are at increased risk for excess visceral adiposity and insulin resistance. Treatment with GH decreases visceral adiposity but worsens glucose metabolism. IGF-I, which mediates many of the effects of GH, improves insulin sensitivity in HIV-negative individuals. OBJECTIVE: Our objective was to determine whether IGF-I, complexed to its major binding protein, IGF-binding protein-3 (IGFBP-3), improves glucose metabolism and alters body fat distribution in HIV-infected patients with abdominal obesity and insulin resistance. METHODS: We conducted a pilot, open-label study in 13 HIV-infected men with excess abdominal adiposity and insulin resistance to assess the effect of 3 months of treatment with IGF-I/IGFBP-3 on glucose metabolism and fat distribution. Glucose metabolism was assessed by oral glucose tolerance test and hyperinsulinemic-euglycemic clamp. Endogenous glucose production (EGP), gluconeogenesis, whole-body lipolysis, and de novo lipogenesis (DNL) were measured with stable isotope infusions. Body composition was assessed by dual-energy x-ray absorptiometry and abdominal computed tomography scan. RESULTS: Glucose tolerance improved and insulin-mediated glucose uptake increased significantly during treatment. EGP increased under fasting conditions, and suppression of EGP by insulin was blunted. Fasting triglycerides decreased significantly in association with a decrease in hepatic DNL. Lean body mass increased and total body fat decreased, whereas visceral adipose tissue did not change. CONCLUSIONS: Treatment with IGF-I/IGFBP-3 improved whole-body glucose uptake and glucose tolerance, while increasing hepatic glucose production. Fasting triglycerides improved, reflecting decreased DNL, and visceral adiposity was unchanged.


Subject(s)
Body Fat Distribution , Glucose/metabolism , HIV Infections/drug therapy , Insulin Resistance , Insulin-Like Growth Factor Binding Protein 3/administration & dosage , Insulin-Like Growth Factor I/administration & dosage , Obesity, Abdominal/drug therapy , Adipose Tissue/drug effects , Adipose Tissue/metabolism , Body Composition/drug effects , Drug Combinations , HIV Infections/blood , HIV Infections/complications , HIV Infections/metabolism , HIV-1/physiology , HIV-Associated Lipodystrophy Syndrome/blood , HIV-Associated Lipodystrophy Syndrome/drug therapy , HIV-Associated Lipodystrophy Syndrome/metabolism , Humans , Insulin-Like Growth Factor Binding Protein 3/adverse effects , Insulin-Like Growth Factor Binding Protein 3/pharmacology , Insulin-Like Growth Factor I/adverse effects , Insulin-Like Growth Factor I/pharmacology , Lipid Metabolism/drug effects , Male , Middle Aged , Obesity, Abdominal/blood , Obesity, Abdominal/etiology , Obesity, Abdominal/metabolism , Pilot Projects
15.
Sleep ; 32(4): 483-90, 2009 Apr.
Article in English | MEDLINE | ID: mdl-19413142

ABSTRACT

STUDY OBJECTIVES: To determine whether slow wave sleep (SWS) is inversely associated with body mass index (BMI) and other measures of body composition. DESIGN: Cross-sectional, observational study. SETTING: Community-based. PARTICIPANTS: 2745 older men from the MrOS Sleep Study who completed polysomnography. INTERVENTIONS: N/A. MEASUREMENTS AND RESULTS: SWS as a percentage of total sleep duration was obtained from in-home, overnight polysomnography. Measures of body composition including BMI, weight, waist circumference and total body fat mass were determined by standard techniques. Other covariates in the analysis were age, race/ethnicity, clinic site, physical activity, respiratory disturbance index (RDI), total sleep time, and sleep efficiency. In the multivariate analysis, there was a significant inverse association between quartiles of SWS and BMI (P-trend = 0.0095). Older men in the lowest quartile of SWS had an average BMI of 27.4 kg/m2, compared to 26.8 for those in the highest quartile of SWS. This association was attenuated in men with RDI > or = 15. Furthermore, participants in the lowest quartile of SWS had a 1.4-fold increased odds for obesity (P = 0.03, 95% CI 1.0, 1.8) compared to those in the highest quartile. A similar inverse association between SWS and waist circumference as well as weight was observed. REM sleep was not associated with measures of body composition. CONCLUSIONS: Independent of sleep duration, percentage time in SWS is inversely associated with BMI and other measures of body composition in this population of older men. Participants in the lowest quartile of SWS (compared to those in the highest quartile) are at increased risk for obesity.


Subject(s)
Body Composition/physiology , Body Mass Index , Polysomnography , Signal Processing, Computer-Assisted , Sleep Stages/physiology , Absorptiometry, Photon , Adipose Tissue/physiopathology , Aged , Aged, 80 and over , Cohort Studies , Humans , Male , Obesity/physiopathology , Sleep Apnea Syndromes/physiopathology , Sleep, REM/physiology , Waist-Hip Ratio
16.
Am J Infect Dis ; 2(3): 159-166, 2006 Sep 30.
Article in English | MEDLINE | ID: mdl-22162956

ABSTRACT

The use of protease inhibitors and non-nucleoside reverse transcriptase inhibitors for the treatment of HIV infection and AIDS has been associated with multiple abnormalities in glucose and lipid metabolism. Specifically, these abnormalities include insulin resistance, increased triglycerides and increased LDL cholesterol levels. The metabolic disturbances are due to a combination of factors, including the direct effect of medications, restoration to health and HIV disease, as well as individual genetic predisposition. Of the available anti-retroviral medications, indinavir has been associated with causing the most insulin resistance and ritonavir with causing the most hypertriglyceridemia.

17.
Curr HIV/AIDS Rep ; 2(1): 39-50, 2005 Feb.
Article in English | MEDLINE | ID: mdl-16091248

ABSTRACT

Since the introduction of HIV protease inhibitors (PIs), disorders of glucose and lipid metabolism have emerged. In dissecting out the direct effect on lipid and glucose metabolism, it has become apparent that individual PIs have different effects on metabolism. Some PIs such as indinavir acutely induce insulin resistance. PIs have also been shown to cause other disorders of glucose metabolism, including impairment of insulin secretion and increased endogenous glucose production. Individual PIs also have different effects on lipid metabolism. Ritonavir predominantly increases triglyceride and very low-density lipoprotein cholesterol levels. Limited studies in HIV-negative volunteers suggest that several of the PIs do not increase low-density lipoprotein cholesterol levels. This review examines the direct effects of PIs on glucose and lipid metabolism by assessing prospective studies of HIV-infected and healthy normal volunteers, and in vitro studies.


Subject(s)
Blood Glucose/drug effects , Glucose/metabolism , HIV Infections/drug therapy , HIV Protease Inhibitors/adverse effects , Hyperlipidemias/chemically induced , Lipid Metabolism , Diabetes Mellitus/chemically induced , HIV Infections/metabolism , HIV Protease Inhibitors/therapeutic use , Humans , Hyperlipidemias/metabolism , Insulin Resistance , Prospective Studies
18.
Curr Infect Dis Rep ; 6(6): 471-482, 2004 Dec.
Article in English | MEDLINE | ID: mdl-15538985

ABSTRACT

Since the introduction of HIV protease inhibitors (PIs), disorders of glucose and lipid metabolism have emerged. In dissecting out the direct effect on lipid and glucose metabolism, it has become apparent that individual PIs have different effects on metabolism. Some PIs such as indinavir acutely induce insulin resistance. PIs have also been shown to cause other disorders of glucose metabolism, including impairment of insulin secretion and increased endogenous glucose production. Individual PIs also have different effects on lipid metabolism. Ritonavir predominantly increases triglyceride and very low-density lipoprotein cholesterol levels. Limited studies in HIV-negative volunteers suggest that several of the PIs do not increase low-density lipoprotein cholesterol levels. This review examines the direct effects of PIs on glucose and lipid metabolism by assessing prospective studies of HIV-infected and healthy normal volunteers, and in vitro studies.

SELECTION OF CITATIONS
SEARCH DETAIL
...